華森製藥(002907.SZ)擬楊勝勇共設成都奧睿藥業 進行腫瘤、免疫1類創新藥物開發等業務
格隆匯6月12日丨華森製藥(002907.SZ)公佈，為響應和推動黨中央關於成渝地區雙城經濟圈建設的重大戰略部署，在西部形成高質量發展的重要增長極，為川渝地區生物高新技術產業發展，攻克影響國民健康的重大疾病做出應有貢獻，同時，助力公司創新藥研發戰略的實現，提升公司市場競爭力，為患者(特別是腫瘤患者)帶來治療確切的產品和診療方案，公司於2020年6月12日與四川大學華西醫院生物治療國家重點實驗室教授、“長江學者獎勵計劃”特聘教授楊勝勇(“創始人”)強強聯合，共同簽訂了《關於共同對外投資設立創新藥研發公司之投資協議書》，雙方共同出資設立成都奧睿藥業有限公司(暫定名，最終以國家市場監督管理部門登記信息為準，“目標公司”)，進行腫瘤、免疫1類創新藥物開發等業務。
此次交易雙方投資總額合計為人民幣4520萬元，目標公司註冊資本為人民幣4520萬元，交易完成後，公司將持有目標公司37.70%的股權。
此次對外投資前，公司創新藥工作已開始推動，2019 年公司在美國設立全資子公司 Pharscin US Inc.，致力於為公司在歐美尋找創新藥合作機會；2020年3月，公司引入首席科學官，並已開始加速內部研發設施、研發隊伍和研發體系的打造與建設。
此次與四川大學楊勝勇教授團隊的合作是響應和推動黨中央關於成渝地區雙城經濟圈建設的重大戰略部署的一次良好契機。此次合作將推動公司創新藥研發工作進一步延伸至具體項目階段，目標公司將以靶向細胞Necroptosis的小分子抑制劑的創新藥物研發項目為起點，通過3到5年時間圍繞國際前沿靶點逐步形成至少2個IND階段項目3個PCC階段項目的研發管線。同時，楊勝勇教授團隊在小分子靶向藥方面深厚的學術造詣是對公司創新藥能力建設的一個有力補充，公司與目標公司在創新藥研發合作方面將形成協同效應，公司創新藥研發戰略將得到更有力的夯實。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
